Tanzania recently reported its first two mpox cases, raising the number of affected countries to 23, officials from the ...

Six weeks after Rwanda-backed rebels captured the eastern Congolese cities of Goma and Bukavu, the region is facing a setback ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

Mpox: Warning over ‘highly infectious’ new variant identified in Congo - The global community needs to ‘step up’ to prevent ...

Severe mpox and long-term sequelae such as severe scarring were more likely to occur among HIV-positive patients with detectable viral loads and low CD4 counts.

Dr. Alex Isakov offers updates and insights for EMS professionals on navigating the infectious disease landscape ...

The results from STOMP reinforce the value of randomized clinical trials during outbreaks of infectious diseases, like mpox,” said Past ACTG Chair Judith Currier M.D., M.Sc. “There was considerable ...

A NIH-led trial found tecovirimat ineffective in reducing mpox lesion healing time or pain relief. The study was halted in 2024, with findings presented at CROI 2025.

The two confirmed infected individuals have symptoms such as rash, fever, and headache, as well as pain in the body and ...

NIH-sponsored trial data offers further evidence to help inform mpox treatment decisions.

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve ...